BIOLASE Inc. (NASDAQ:BIOL) has a beta value of 1.57 and has seen 1.78 million shares traded in the last trading session. The company, currently valued at $113.40M, closed the last trade at $0.73 per share which meant it lost -$0.02 on the day or -3.20% during that session. The BIOL stock price is -106.85% off its 52-week high price of $1.51 and 65.75% above the 52-week low of $0.25. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.15 million shares traded. The 3-month trading volume is 4.62 million shares.
The consensus among analysts is that BIOLASE Inc. (BIOL) is a Buy stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.04.
BIOLASE Inc. (NASDAQ:BIOL) trade information
Sporting -3.20% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Friday, 09/03/21 when the BIOL stock price touched $0.73 or saw a rise of 10.98%. Year-to-date, BIOLASE Inc. shares have moved 74.23%, while the 5-day performance has seen it change -1.49%. Over the past 30 days, the shares of BIOLASE Inc. (NASDAQ:BIOL) have changed 28.65%. Short interest in the company has seen 5.25 million shares shorted with days to cover at 1.42.
Wall Street analysts have a consensus price target for the stock at $2.25, which means that the shares’ value could jump 67.56% from current levels. The projected low price target is $2.00 while the price target rests at a high of $3.00. In that case, then, we find that the current price level is -310.96% off the targeted high while a plunge would see the stock gain -173.97% from current levels.
BIOLASE Inc. (BIOL) estimates and forecasts
Figures show that BIOLASE Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -16.66% over the past 6 months, with this year growth rate of 80.36%, compared to 25.30% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 66.70% and 85.70% for the next quarter. Revenue growth from the last financial year stood is estimated to be 60.90%.
4 analysts offering their estimates for the company have set an average revenue estimate of $9.13 million for the current quarter. 4 have an estimated revenue figure of $8.78 million for the next quarter concluding in Sep 2021. Year-ago sales stood $2.94 million and $6.5 million respectively for this quarter and the next, and analysts expect sales will grow by 210.90% for the current quarter and 35.10% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 20.30% over the past 5 years. Earnings growth for 2021 is a modest 27.30% while over the next 5 years, the company’s earnings are expected to increase by 20.00%.
BIOLASE Inc. is expected to release its next earnings report on March 25 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
BIOLASE Inc. (NASDAQ:BIOL)’s Major holders
Insiders own 5.39% of the company shares, while shares held by institutions stand at 18.08% with a share float percentage of 19.11%. Investors are also buoyed by the number of investors in a company, with BIOLASE Inc. having a total of 45 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 7.34 million shares worth more than $6.18 million. As of Mar 30, 2021, Vanguard Group, Inc. (The) held 4.88% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 3.58 million shares as of Mar 30, 2021. The firm’s total holdings are worth over $3.02 million and represent 2.38% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Mar 30, 2021, the former fund manager holds about 2.92% shares in the company for having 4.39 million shares of worth $3.7 million while later fund manager owns 2.76 million shares of worth $2.32 million as of Mar 30, 2021, which makes it owner of about 1.83% of company’s outstanding stock.